Author: admin

Latest Research on Cable Type in the Submarine Cable Systems Market by MarketsandMarkets™

“Submarine Cable Systems Market”
The global Submarine Cable Systems Market Size was estimated at USD 18.16 billion in 2024 and is predicted to increase from USD 19.95 billion in 2025 to approximately USD 33.75 billion by 2030, expanding at a CAGR of 11.1% from 2025 to 2030.

The report “Submarine Cable Systems Market by Cable Type (Communication Cable, Power Cable), Component (Dry Plant Product, Wet Plant Product), Insulation (Cross-linked Polyethylene, Oil-Impregnated Paper) and Type (Single Core, Multicore) – Global Forecast to 2030” The global submarine cable systems market is anticipated to grow from USD 19.95 billion in 2025 to USD 33.75 billion in 2030, at a compound annual growth rate (CAGR) of 11.1%. Most global internet traffic depends on submarine cables, and almost everyone relies on the internet for day-to-day activities. The world is connected through the Internet; thus, global traffic is increasing every other day. About half of the global internet traffic comes from Asia Pacific, which, in turn, is driving the demand for submarine communication cables. Additionally, the increasing global demand for renewable energy, particularly offshore wind farms, is a key driver of the submarine cable system market, necessitating extensive power cable networks for efficient energy transmission.

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=184625

Browse 211 market data Tables and 82 Figures spread through 290 Pages and in-depth TOC on “Submarine Cable Systems Market”

View detailed Table of Content here – https://www.marketsandmarkets.com/Market-Reports/submarine-cable-system-market-184625.html

Single Core Segment to Hold Largest Market Share in 2025

Single core submarine power cables constitute multiconductor systems consisting of conductors, insulations, and lead or aluminum sheaths with a single propagation mode to prevent moisture ingress in them. Single core features a higher bandwidth than multicore cables and, hence, a high data transmission rate. These cables are suitable for covering longer lengths as they experience lower reverse currents than multicore cables. The high value of the segment is also attributed to the high cost of installation, connectors, and systems.

High-Voltage Segment to Exhibit Highest CAGR Between 2025 and 2030

Submarine power cables with a voltage above 33 kV are considered high-voltage cables. These cables enable the integration of renewable energy into the existing grid and the extension of the system to single points, such as offshore wind farms or oil & gas plants. High-voltage submarine power cables comprise conductors and insulation layers. These are usually 3-core armored cables with copper or aluminum conductors. XLPE is the most widely used insulation for high-voltage submarine power cables owing to its higher current rating than polyvinyl chloride (PVC). These cables enable efficient power transmission owing to their low transmission losses. The increasing requirement for interconnecting lands and the growing demand for power generation from offshore plants using renewable sources have led to the growth of the global high-voltage Submarine Power Cable Industry.

Inquiry Before Buying @ https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=184625

Europe to Capture Largest Market Share in 2025

Europe is anticipated to dominate a significant portion of the submarine power cables market in 2025. With the European Union (EU) targeting a minimum renewable energy in the overall energy mix by 2030, the region is transitioning from fossil fuels to renewable sources, such as hydropower, solar energy, wind power, and biofuels, driving substantial demand for submarine cable systems. Furthermore, Europe hosts numerous offshore oil & gas projects, notably in the UK, Norway, the Netherlands, Italy, and Denmark. These projects, including Ekofisk (Norway), Montrose (UK), Forties (UK), Eldfisk (Norway), Dan (Denmark), Brent (Norway), Frigg (UK), Beryl (UK), Sleipner (Norway), and Statford (Norway), are actively engaged in exploration and production activities, attracting fresh investments in the offshore oil & gas sector and subsequently fueling demand for submarine power cables in the region. Germany and the UK are poised for rapid growth during the forecast period.

Major Players Operating in the Submarine Cable Systems Companies are Alcatel Submarine Networks (France), Prysmian S.p.A (Italy), SubCom, LLC (US), NEC Corporation (Japan), and Nexans (France).

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America’s Best Management Consulting Firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.

Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.

The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Delray Beach
State: https://www.marketsandmarkets.com/Market-Reports/submarine-cable-system-market-184625.html
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/submarine-cable-system-market-184625.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Latest Research on Cable Type in the Submarine Cable Systems Market by MarketsandMarkets™

Causal AI Market 2030: Size, Share, Future Scope, Latest Trends, Emerging Leaders, Applications and Driving Factors

“IBM (US), Logility (US), CausaLens (UK), Aitia (US), Causely (US), Geminos (US), Data Poem (US), CausaAI (Netherlands), Causa (UK), Lifesight (US), Actable AI (UK).”
Causal AI Market by Offering (Causal AI Platforms, Causal Discovery, Causal Inference, Causal Modelling, Root Cause Analysis), Application (Financial Management, Sales & Customer Management, Operations & Supply Chain Management) – Global Forecast to 2030.

The global Causal AI Market is expected to develop at a compound annual growth rate (CAGR) of 41.8%, from an estimated USD 56.2 million in 2024 to USD 456.8 million by 2030. The market for causal AI is expanding due to the increasing need for causal insights to improve machine learning models’ decision-making. Understanding cause-and-effect relationships rather than only examining correlations has become more important due to the growing usage of AI in sectors including supply chain, healthcare, and finance. To enhance forecasting and strategies, businesses are investing heavily in sophisticated causal inference approaches, incorporating specialist information, and employing cutting-edge simulation tools.

Download PDF Brochure@ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=162494083

The causal AI market is witnessing sharp expansion as it can address important issues that traditional AI finds difficult to resolve. This need for transparency, trust, and actionable insights is driving the adoption of causal AI. The adoption of causal AI is being driven by the demand for transparency, trust, and actionable insights in critical sectors such as healthcare, finance, and supply chain management. Causal AI is an essential tool for companies wanting to remain competitive in a data-driven world, as it can reveal cause-and-effect relationships and improve decision-making. For example, companies are using causal AI to comprehend the real factors behind customer behavior, improve marketing tactics, or forecast the consequences of operational choices. Moreover, improvements in data accessibility, computing capabilities, and user-friendly interfaces are reducing obstacles for organizations of all sizes to adopt causal AI solutions.

By offering, causal inference tools segment will register the fastest growth rate over the forecast period owing to enhanced decision making across diverse scenarios

Causal inference tools are becoming the most rapidly expanding segment in the causal AI market because of their adaptability and availability in various industries. These tools give organizations the ability to discover cause-and-effect relationships within their data, allowing for accurate decision-making in fields such as marketing, healthcare, and operations. Businesses are starting to realize the drawbacks of AI that relies on correlations, as it only detects patterns without providing explanations for outcomes. Causal inference tools help to close this divide by providing useful information that can be used to shape strategies, like determining which marketing campaigns increase customer engagement or studying the factors that impact patient recovery. Their growth is also fueled by the availability of intuitive, user-friendly interfaces that allow non-technical users to apply complex causal analysis without requiring deep expertise. Causal inference tools are becoming essential as organizations require more accountability and transparency in their decision-making, leading to their quick adoption.

Rising adoption of causal AI to augment financial decision making with cause-and-effect analysis will push BFSI as the largest vertical by market size in 2024

The BFSI vertical is poised to hold the largest market share in the causal AI market, fueled by its requirements for clarity, risk control, and practical information. Causal AI helps financial institutions tackle ever-changing, regulated environments where comprehending the reasons behind events is just as important as foreseeing them. For instance, JPMorgan Chase utilizes causal AI to pinpoint the underlying reasons for customer turnover, enabling specific actions to keep valuable customers. In the same way, Citibank employs causal models to evaluate the effects of different credit risk strategies, leading to enhanced loan approval procedures and a decrease in defaults. In the insurance industry, firms such as Allstate have implemented causal AI to enhance the identification of claim fraud by pinpointing actions that are closely linked to fraudulent behavior, resulting in a documented decrease of over 10% in unnoticed fraud. In addition, insurance companies employ causal AI to customize policy suggestions by examining the specific reasons for customer preferences, greatly improving customer contentment. Compliance with regulations continues to drive the increase in adoption. For example, HSBC uses causal AI to comply with AML laws by identifying causal connections in transaction data, simplifying investigations, and avoiding significant penalties. The use of causal AI in precise decision-making, along with its demonstrated effects on profitability and compliance, cements BFSI as the top vertical in the market.

Asia Pacific is set to become the fastest growing region over the forecast period, fueled by increasing investments in responsible AI deployment for decision-making

Several key factors are driving rapid growth in the causal AI market in the Asia Pacific. Governments and businesses in the APAC region, specifically in nations such as China, Japan, and India, are making significant investments in AI innovation to promote the development and utilization of causal AI technologies. Sectors like healthcare and finance in the region are utilizing causal AI to enhance decision-making and operational efficiency. Hospitals in Singapore are using causal AI in healthcare to enhance treatment plans, leading to a substantial enhancement in patient results. Banks in India are using causal AI in the financial industry to improve fraud detection, leading to a significant decrease in fraudulent transactions. Manufacturing hubs in countries like Vietnam and Thailand are adopting causal AI to predict and mitigate disruptions. This trend is also assisted by the regional regulatory landscape, which favors responsible artificial intelligence practices, increasing the market demand for causal models that are both transparent and free from bias.

Request Sample Pages@ https://www.marketsandmarkets.com/requestsampleNew.asp?id=162494083

Unique Features in the Causal AI Market

The Causal AI Market is distinguished by its ability to move beyond traditional correlation-based analytics and uncover true cause-and-effect relationships within complex datasets. Unlike conventional AI models that primarily identify patterns, causal AI leverages causal inference techniques, structural causal models, and intervention analysis to determine why specific outcomes occur. This capability enables organizations to make more reliable decisions, improve forecasting accuracy, and reduce risks associated with misleading correlations.

A major unique feature of the Causal AI Market is its advanced explainability. Causal AI provides transparent reasoning by revealing the underlying drivers behind predictions and outcomes rather than simply highlighting associated variables. This makes AI decisions easier to interpret, audit, and trust, which is particularly valuable in regulated industries such as healthcare, finance, manufacturing, and government. The technology aligns closely with growing demands for explainable and responsible AI systems.

Another defining characteristic is counterfactual reasoning, often referred to as “what-if” analysis. Causal AI systems can simulate alternative scenarios and estimate the impact of potential actions before they are implemented. Organizations can evaluate interventions, predict consequences, and identify optimal strategies without conducting costly real-world experiments. This capability significantly enhances strategic planning and operational decision-making.

Major Highlights of the Causal AI Market

The Causal AI Market is experiencing strong growth as organizations increasingly seek AI solutions that provide actionable insights rather than simple predictive outputs. Businesses across industries are adopting causal AI to understand the underlying drivers of outcomes, enabling more informed decision-making, improved operational efficiency, and better risk management. The market’s expansion is supported by the growing demand for transparent and explainable AI systems that can deliver trustworthy recommendations.

A major highlight of the market is the rising adoption of causal inference and structural causal modeling technologies. Enterprises are leveraging these capabilities to identify cause-and-effect relationships within complex datasets, helping them optimize business processes, enhance forecasting accuracy, and improve strategic planning. This shift from correlation-based analytics to causality-driven intelligence is creating new opportunities for AI deployment.

The healthcare sector represents one of the most significant application areas for causal AI. Healthcare providers, pharmaceutical companies, and research institutions are utilizing causal models to support clinical decision-making, treatment optimization, drug discovery, and patient outcome analysis. The ability to understand causal factors behind diseases and treatment responses is accelerating adoption within the medical field.

Inquire Before Buying@ https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=162494083

Top Companies in the Causal AI Market

Some leading players in the Causal AI market include IBM (US), Google (US), Microsoft (US), Dynatrace (US), Cognizant (US), Logility (US), Datarobot (US), CausaLens (UK), Aitia (US), Taskade (US), Causely (US), Causaly (UK), Causality Link (US), Xplain data (Germany), Parabole.AI (US), Datma (US), Incrmntl (Israel), Scalnyx (France), Geminos (US), Data Poem (US), CausaAI (Netherlands), Causa (UK), Lifesight (US), Actable AI (UK), biotx.ai (Germany), Howso (US), VELDT (Japan), and CML Insight (US). These players have adopted various organic and inorganic growth strategies, such as new product launches, partnerships and collaborations, and mergers and acquisitions, to expand their presence in the Causal AI market.

IBM

IBM is a world-renowned company that leads the way in delivering creative AI solutions, with a particular emphasis on causal AI. Founded in 1911, IBM has been a leader in AI technology, providing unique tools and platforms for creating advanced models. The field of Causal AI, a significant area of AI research, aims to improve decision-making in difficult scenarios by understanding cause-and-effect connections, rather than just looking at correlations. IBM is at the forefront of the industry, supplying companies with necessary resources to develop AI systems capable of analyzing data, forecasting outcomes, and recognizing root problems. IBM offers customized artificial intelligence solutions and tools tailored for companies to leverage data in the healthcare, finance, and supply chain sectors. IBM enhances application capabilities for natural language processing, computer vision, and predictive analytics through the integration of causal modeling techniques with conventional artificial intelligence methods. IBM’s worldwide knowledge and advanced technology help businesses incorporate causal frameworks, resulting in enhanced transparency and effectiveness in AI systems. By providing managed services, pre-built frameworks, and customizable tools, IBM enables organizations to fulfill their specific needs. IBM’s emphasis on causal AI allows businesses to shift from responding to situations after they happen to making proactive decisions, promoting innovation and adaptability in the face of evolving AI technologies.

Microsoft

Microsoft is a major player in the worldwide artificial intelligence (AI) industry, specifically emphasizing on causal AI. Since 1975, Microsoft has been a leader in technological innovation, offering advanced tools and platforms to help companies create and enhance AI solutions. Causal AI, a critical focus area, surpasses conventional AI by recognizing cause-and-effect associations, facilitating better forecasts and well-informed choices in ever-changing environments. Microsoft provides a strong set of solutions, such as Azure AI and specialized frameworks, to assist with causal AI applications in various industries like healthcare, retail, and finance. These tools combine causal inference and machine learning to improve natural language processing, computer vision, and predictive analytics, ensuring that AI systems provide useful insights and increased transparency. Through its vast worldwide network, research knowledge, and flexible infrastructure, Microsoft helps companies integrate causal reasoning into their AI processes.

Google

Google is a major global contributor to the development of artificial intelligence, with a growing emphasis on causal AI. Google was founded in 1998 and has revolutionized the tech industry by launching innovative tools and platforms for building smart, flexible systems. Causal AI is an advanced AI system created to discover causal relationships, improving prediction and decision-making in real-world situations. Google offers a variety of advanced artificial intelligence options through its Google Cloud AI and TensorFlow platforms, as well as research developments from DeepMind and Google Research. These products blend machine learning with causal inference methods to enhance their application in natural language processing, computer vision, and predictive analytics. Sectors like healthcare, logistics, and e-commerce see advantages from these advancements, as causal AI helps systems to think efficiently, providing practical knowledge and improving the process of making decisions.

Dynatrace

Dynatrace specializes in software intelligence solutions, providing AI-driven monitoring and observability tools for cloud environments. With its advanced causal AI capabilities, Dynatrace helps organizations identify root causes of performance issues and anomalies, ensuring optimized application performance, improved user experiences, and streamlined IT operations.

Datarobot

DataRobot is a leading AI platform provider that empowers organizations to automate and accelerate predictive analytics. Leveraging advanced machine learning and causal AI capabilities, DataRobot helps businesses uncover cause-and-effect relationships in data, enabling better decision-making and actionable insights across various industries, including healthcare, finance, and retail.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: https://www.marketsandmarkets.com/Market-Reports/causal-ai-market-162494083.html
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/causal-ai-market-162494083.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Causal AI Market 2030: Size, Share, Future Scope, Latest Trends, Emerging Leaders, Applications and Driving Factors

Data Diode Market Growth Driven Worth USD 0.77 Billion by 2031, at a CAGR of 6.6% – Report by MarketsandMarkets™

“Naonworks (South Korea), Waterfall Security Solutions (Israel), Infodas (Germany), Siemens (Germany), OPSWAT (US), Advenica (Sweden), Everfox (US), Garland Technology (US), Arbit Cyber Defence Systems (Denmark), Fibersystem (Sweden), VADO Security Technologies (Israel).”
Data Diode Market by Form Factor (DIN Rail, Embedded/OEM Modules & PCIe Systems), Application Area (Operational Process Visibility & Analytics, OT Security Monitoring & Compliance, Physical Security & Surveillance Monitoring) – Global Forecast to 2031.

The data diode market is expected to expand at a compound annual growth rate (CAGR) of 6.6% from USD 0.56 million in 2026 to USD 0.77 billion by 2031. Data diode solutions that offer hardware-enforced network isolation are in high demand because to the increasing use of zero-trust security frameworks in critical infrastructure and industrial settings. In order to reinforce OT network segmentation, block unwanted access, and secure communication between IT and operational systems against evolving cyber threats, organizations are increasingly implementing unidirectional security technologies.

Download PDF Brochure@ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=36397871

By organization size, the SMEs segment is estimated to register the highest CAGR during the forecast period.

Small and medium-sized enterprises are increasingly adopting data diode solutions as cyber threats targeting industrial and operational environments continue to rise. SMEs across manufacturing, energy, transportation, and utilities are expanding digital operations, remote monitoring, and connected industrial systems, increasing exposure to ransomware and OT-focused attacks. According to IBM X-Force, ransomware and infrastructure-related cyberattacks continue to impact organizations of all sizes, including smaller industrial operators. As a result, SMEs are increasingly investing in cost-effective unidirectional security solutions to strengthen OT network segmentation, secure operational data transfer, and protect critical systems from unauthorized access and operational disruptions while supporting regulatory compliance and business continuity requirements.

By application area, the security domain and the cross-classification information exchange segment is estimated to lead the market during the forecast period.

Security domain and cross-classification information exchange applications account for a major share of the data diode market due to growing demand for secure communication between networks operating at different security levels. Governments, defense agencies, critical infrastructure operators, and intelligence organizations increasingly require secure transfer of sensitive operational data between classified and unclassified environments without exposing high-security systems to inbound cyber threats. Data diode solutions provide hardware-enforced one-way communication that supports secure cross-domain information exchange, network segmentation, and protection of mission-critical systems. Rising geopolitical tensions, cyber warfare risks, and increasing focus on national cyber resilience are further accelerating deployment across defense, government, energy, and industrial security environments.

By region, Asia Pacific is estimated to register the highest CAGR during the forecast period.

Asia Pacific is witnessing strong growth in the data diode market due to rapid industrialization, increasing investments in critical infrastructure modernization, and growing adoption of smart manufacturing and industrial automation technologies across countries such as China, India, Japan, South Korea, and Singapore. Governments and industrial operators across the region are increasingly strengthening cybersecurity frameworks to protect energy grids, transportation systems, manufacturing facilities, and defense infrastructure from rising cyber threats and ransomware attacks. Expanding IT-OT convergence, growth of industrial IoT deployments, and rising investments in renewable energy and smart city infrastructure are further accelerating demand for secure one-way communication and OT network isolation solutions across the region.

Request Sample Pages@ https://www.marketsandmarkets.com/requestsampleNew.asp?id=36397871

Unique Features in the Data Diode Market

The Data Diode Market is distinguished by its focus on hardware-enforced unidirectional communication, which physically allows data to travel in only one direction. Unlike traditional firewalls and software-based cybersecurity solutions, data diodes eliminate inbound attack paths at the hardware level, making them highly suitable for critical infrastructure, defense networks, industrial control systems (ICS), and operational technology (OT) environments where maximum security is required.

Another unique feature of the market is its growing adoption across IT-OT convergence environments. As industries increasingly connect operational networks with enterprise and cloud platforms, data diodes provide secure data sharing without exposing critical systems to cyber threats. This capability supports real-time monitoring, industrial analytics, and remote asset visibility while maintaining strict network isolation.

The market also stands out for its emphasis on high-assurance security and regulatory compliance. Data diode solutions are widely deployed in sectors such as energy, nuclear facilities, transportation, defense, and government institutions where compliance with stringent cybersecurity regulations and security certifications is essential. Their deterministic one-way communication architecture helps organizations meet regulatory requirements related to critical infrastructure protection and classified information security.

Major Highlights of the Data Diode Market

The Data Diode Market is witnessing strong growth due to the rising need for hardware-based cybersecurity solutions that provide physically enforced one-way data transfer. Organizations managing critical infrastructure are increasingly deploying data diodes to prevent unauthorized network access, ransomware attacks, and advanced persistent threats (APTs). Growing cybersecurity concerns and the expansion of digital infrastructure continue to accelerate market demand globally.

A major highlight of the market is the increasing adoption of data diodes across critical infrastructure sectors, including energy, power, oil & gas, transportation, aerospace, defense, and government networks. These industries require highly secure communication channels that protect operational systems while enabling real-time data monitoring and analytics. Regulatory mandates and national security initiatives are further strengthening deployment across these sectors.

The market is being driven by the rapid convergence of Information Technology (IT) and Operational Technology (OT) environments. As industrial organizations connect operational systems with enterprise networks and cloud platforms, the need for secure, unidirectional communication has increased significantly. Data diodes enable safe data exchange without exposing critical assets to external cyber risks, making them essential for Industry 4.0 and smart infrastructure projects.

Inquire Before Buying@ https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=36397871

Top Companies in the Data Diode Market

The data diode market is led by some of the globally established players, such as Forcepoint (US), Naonworks (South Korea), Waterfall Security Solutions (Israel), Infodas (Germany), Siemens (Germany), OPSWAT (US), Advenica (Sweden), Everfox (US), Garland Technology (US), Arbit Cyber Defence Systems (Denmark), Fibersystem (Sweden), VADO Security Technologies (Israel), Chipspirit (India), Sunhillo (US), Link22 (Sweden), 4Secure (UK), Stratign (UAE), Oakdoor (UK), BAE Systems (UK), ST Engineering (Singapore), Owl Cyber Defense (US), and Nexor (UK). These market players have adopted various strategies, such as product launches, partnerships, contracts, expansions, and acquisitions, to strengthen their position in the Data diode market. Organic and inorganic strategies have enabled market players to expand globally by providing emotion detection and response solutions.

OPSWAT (US) is a cybersecurity company focused on protecting critical infrastructure and industrial environments through OT security, secure data transfer, and unidirectional gateway technologies. In the data diode market, OPSWAT provides hardware-enforced one-way communication solutions through its MetaDefender Optical Diode and MetaDefender NetWall portfolio, enabling secure data transfer between isolated IT and OT networks. Its offerings support protocol replication, real-time industrial monitoring, secure file transfer, and protection against network-borne threats across sectors such as energy, manufacturing, transportation, defense, and utilities. The company’s solutions also support industrial cybersecurity compliance frameworks and high-security operational environments requiring secure network segmentation and air-gap reinforcement.

Infodas (Germany) is a cybersecurity and cross-domain security solutions provider specializing in high-assurance secure communication technologies for government, defense, and critical infrastructure sectors. In the data diode market, Infodas offers its SDoT Software Data Diode solution designed for secure unidirectional data transmission across classified and industrial environments. The company’s solutions support secure one-way communication, network segmentation, and protection of sensitive OT and IT systems through software-defined data diode architectures. Its offerings are deployed across military, maritime, industrial, and critical infrastructure environments requiring high-security certified communication systems and compliance with NATO, EU, and German cybersecurity standards.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: https://www.marketsandmarkets.com/Market-Reports/data-diode-market-36397871.html
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/data-diode-market-36397871.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Data Diode Market Growth Driven Worth USD 0.77 Billion by 2031, at a CAGR of 6.6% – Report by MarketsandMarkets™

Poultry Processing Equipment Market to Reach $8.61 billion by 2035, Growing at a CAGR of 6.3% – Exclusive Report by MarketsandMarkets™

“MarketsandMarkets™”
Poultry Processing Equipment Market by Equipment Type (Live Bird Handling, Slaughtering & Defeathering, Evisceration, Cut-up & Portioning, Deboning & Filleting, Others), Product Type, Automation Level, Plant Capacity, and Region – Global Forecast to 2035

According to a research report published by MarketsandMarkets™, The poultry processing equipment market is estimated to be USD 4.97 billion in 2026 and is projected to reach USD 8.61 billion by 2035, registering a CAGR of 6.3% from 2026 to 2035. The market for poultry processing machinery is experiencing substantial growth mainly because of the increased global demand for both poultry meat products and already processed poultry items. Poultry processing machinery plays a crucial role in ensuring efficiency, quality, and hygiene while also facilitating large-scale production in processing plants. The increased demand for ready-to-cook and ready-to-eat poultry products is prompting manufacturing companies to switch to technologically advanced systems of slaughtering, defeathering, evisceration, chilling, and deboning. Increasing focus on food safety regulations and labor cost reduction is further driving the adoption of advanced poultry processing equipment globally.

The other significant reason that has resulted in market expansion includes the growth of commercial poultry production as well as poultry processing plants, especially in emerging economies. The growing use of automation, robotic technologies, and AI-powered inspection machines, along with high-capacity processing lines, is leading to increased output rates, reduced contamination levels, and improved efficiency. Additionally, significant investments from quick service restaurants, food retailers, and meat processors focusing on exports have heightened the demand for high-speed poultry processing equipment. Furthermore, an increasing awareness of meat processing hygiene and a rising demand for energy-efficient and sustainable meat processing methods are contributing to the growth of the global poultry processing equipment market.

Poultry Processing Equipment Market

Market Size and Growth Forecast

  • Market Size in 2026 (Value): USD 4.97 BN
  • Market Forecast in 2035 (Value): USD 8.61 BN
  • Growth Rate: CAGR of 6.3% from 2026 to 2035
  • Years Considered: 2022–2035
  • Base Year: 2025
  • Forecast Period: 2026–2035
  • Units Considered: Value (USD Million/Billion), Volume (KT)
  • Report Coverage: Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, and Trends

 

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=1320

By equipment type, quality control and inspection segment to exhibit highest growth rate during forecast period.

Quality control and inspection equipment has become the fastest-growing category among the equipment types used for poultry processing due to the growing concern for safety, quality, and compliance with regulations regarding poultry products. Advanced technologies like X-ray inspection, vision inspection, metal detection, and quality management equipment have been adopted by processors to reduce contamination and improve product quality and efficiency. Growing consumer preference for poultry products that are hygienically processed and strict food safety regulations are driving the use of quality inspection equipment.

By product type, pre-cooked segment to register highest CAGR during forecast period.

By product type, the pre-cooked segment is expected to grow at the highest rate, owing to the increasing demand for convenient, ready-to-eat, and time-saving food products among consumers. The rising popularity of frozen meals, quick service restaurants, and processed poultry snacks is driving poultry processors and poultry producers across the world to invest in advanced cooking, chilling, and portioning equipment. Changing lifestyles and increasing urbanization, in combination with the growing demand for shelf-stable value-added poultry products, are driving the growth of the pre-cooked product segment further.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=1320

By region, Asia Pacific to be fastest-growing market for poultry processing equipment during forecast period.

Asia Pacific is projected to be the fastest-growing market for poultry processing equipment owing to rapid growth in commercial poultry production operations, an increase in poultry meat consumption, and significant investments made in advanced facilities in nations like China, India, Japan, and Thailand. Increased urbanization, shifting consumption trends toward healthy foods, and increased demand for processed poultry meat products have compelled poultry processing companies to invest in automated and high-throughput equipment. Apart from this, enhanced food safety measures, rising exports of poultry meat products, and the presence of rapidly growing fast-food restaurants are boosting market growth.

The report profiles key players such as JBT Marel Corporation (US), GEA Group Aktiengesellschaft (Germany), BAADER Group (Germany), Meyn Food Processing Technology B.V. (Netherlands), Middleby Corporation (US), Duravant LLC (US), Mayekawa Mfg. Co., Ltd. (Japan), Bayle SA (France), Cattaruzzi Srl (Italy), Drobtech (Poland), Cantrell Gainco Group, Inc. (US), Jilin SSK Electromechanical Co., Ltd. (China), Dutch Poultry Technology B.V. (Netherlands), Meitech (Brazil), and Wrightfield Ltd. (UK), among others.

Recent Developments in the Poultry Processing Equipment Industry:

  • February 2026: JBT Marel expanded its manufacturing and testing capabilities in the US to support growing demand for automated protein processing solutions, including poultry chilling, portioning, and marination systems.
  • May 2025: BAADER inaugurated its first Asian production facility in Malaysia to enhance regional manufacturing and service capabilities for protein processing equipment, including poultry processing systems.
  • February 2024: Duravant acquired Ferdinand Henneken GmbH to expand its protein processing equipment portfolio, including marination, tumbling, and injection technologies relevant to poultry value-added processing.

 

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America’s Best Management Consulting Firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.

Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.

The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: https://www.marketsandmarkets.com/Market-Reports/poultry-processing-equipment-market-1320.html
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/poultry-processing-equipment-market-1320.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Poultry Processing Equipment Market to Reach $8.61 billion by 2035, Growing at a CAGR of 6.3% – Exclusive Report by MarketsandMarkets™

Europe Biostimulants Market Repot 2025-2030: Future Business Growth, Revenue, Regional Analysis, and Top Companies

“MarketsandMarkets™”
Europe Biostimulants Market by Active Ingredient (Humic Substances, Seaweed Extracts, Amino Acids, Minerals & Vitamins), Crop Type, Mode Of Application (Foliar Treatment, Soil Treatment), and Form – Forecast To 2030

The Europe biostimulants market is projected to reach USD 3.08 billion by 2030, at a CAGR of 11.4% from 2025 to 2030. The Europe biostimulants market is experiencing steady growth, driven by increasing adoption among farmers, agribusinesses, and commercial growers seeking sustainable, eco-friendly solutions for crop enhancement. Adoption is particularly strong in key markets such as Germany, France, Italy, Spain, and the Netherlands, where biostimulants are applied across cereals, oilseeds, fruits, vegetables, and high-value specialty crops to improve nutrient use efficiency, stress tolerance, and yield stability. Growing awareness of soil health, climate variability, and the benefits of microbial, seaweed, and amino-acid-based products is supporting broader uptake. Furthermore, the integration of digital agronomy platforms, precision agriculture tools, and strong distribution networks is facilitating efficient application and faster adoption, expanding the market across both large-scale commercial farms and specialized high-value crop producers throughout Europe.

Europe Biostimulants Market

Market Size and Growth Forecast

  • Market Size in 2024 (Value): USD 1.62 Billion
  • Market Forecast in 2030 (value): USD 3.08 Billion
  • Growth Rate: CAGR of 11.4% during 2025-2030
  • Years Considered: 2020-2030
  • Base Year: 2024
  • Forecast Period: 2025-2030
  • Units Considered: Value (USD Million/Billion)
  • Report Coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends

 

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=16226008

The liquid segment holds a significant share in the form segment of the Europe biostimulants market.

In the Europe biostimulants market, the liquid segment holds a significant share within the form category, owing to its ease of application, rapid absorption, and compatibility with existing crop management practices. Liquid biostimulants allow precise dosing through foliar sprays, fertigation, and seed treatments, making them suitable for a wide range of crops, including cereals, fruits, vegetables, and specialty crops. Their formulation flexibility and uniform distribution support enhanced nutrient uptake, stress resilience, and overall crop performance, aligning with Europe’s focus on sustainable, low-input, and high-efficiency farming practices. Continuous innovation in stabilized and concentrated liquid products further reinforces their dominant position in the market.

By crop type, the cereals & grains segment is expected to grow at a significant rate in the Europe biostimulants market.

In the Europe biostimulants market, the cereals & grains segment is expected to grow at a significant rate, driven by the region’s large-scale cultivation of wheat, barley, maize, and other staple crops. Increasing regulatory restrictions on synthetic chemical pesticides, coupled with growing demand for sustainable and residue-free crop protection solutions, are encouraging farmers to adopt biopesticides in cereal production. Biopesticides, including microbial, botanical, and biochemical formulations, help manage key pests and diseases while supporting soil health and environmental sustainability. Additionally, integration with precision agriculture tools and advanced crop management practices is accelerating adoption, positioning cereals and grains as a high-growth segment in Europe’s biostimulants landscape.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=16226008

By country, the UK holds a significant share in the Europe biostimulants market.

The UK holds a significant share in the Europe biostimulants market, supported by its technologically advanced agricultural sector, strong focus on sustainability, and well-established regulatory framework for eco-friendly inputs. UK farmers and agribusinesses are increasingly adopting microbial, seaweed-based, and amino-acid biostimulants to enhance nutrient use efficiency, improve tolerance to abiotic stresses, and stabilize yields across cereals, horticultural crops, and high-value specialty crops. The country’s widespread adoption of precision agriculture and digital farming platforms enables optimized biostimulant application, improving both efficacy and input efficiency. Additionally, strong distribution networks, growing awareness of soil health, and government support for sustainable farming practices have reinforced the UK’s leading position in Europe’s biostimulants market, making it a key growth hub for domestic and multinational players.

Leading Europe Biostimulants Companies:

The key companies operating in the Europe biostimulants market include Syngenta Group (Switzerland), BASF SE (Germany), Bayer AG (Germany), Isagro S.P.A. (Italy), Corteva Agriscience (US), Biostadt India Limited (India), Biolchim S.p.A. (Italy), Koppert Biological Systems B.V. (Netherlands), Stoller Europe (France), Seipasa S.A. (Spain), Valagro S.P.A. (Italy), Novonesis A/S (Denmark), UPL Limited (India), Italpollina S.P.A. (Italy), and Tradecorp International S.A. (Spain).

Recent Developments in the Europe Biostimulants Industry:

  • October 2024: Acadian Seaplants Limited and BASF formed a strategic partnership to develop innovative agricultural solutions, providing climate-resilient products that enhance crop yield and quality. Under this, BASF will integrate Acadian’s advanced biostimulant technology into its comprehensive chemistry and biological portfolio, expanding its sustainable crop solutions.
  • October 2024: Elicit Plant and BASF France—Agro Division partnered for the 2024-2025 campaign to advance the development of the biostimulants EliSun-a and EliGrain-a, targeting the sunflower and cereal markets in France.
  • April 2024: PI Industries acquired Plant Health Care (PHC), a company specializing in peptide- and protein-based biocontrol and biostimulant products.
  • March 2024: FMC Corporation announced a collaboration in Canada with Novonesis, formerly Novozymes A/S, a leader in plant biosolutions. This agreement is part of FMC’s strategic plan to expand its biologicals platform in key markets.

 

Make an Inquiry: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=16226008

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America’s Best Management Consulting Firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.

Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.

The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: https://www.marketsandmarkets.com/Market-Reports/europe-biostimulants-market-16226008.html
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/europe-biostimulants-market-16226008.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Europe Biostimulants Market Repot 2025-2030: Future Business Growth, Revenue, Regional Analysis, and Top Companies

IGC Pharma’s (NYSE: IGC) CEO Appears on Bloomberg TV Discussing Alzheimer’s Fast-Acting IGC-AD1 Pharmaceutical Therapeutic – More Stocks Inside

IGC Pharma, Inc. (NYSE: IGC), a clinical-stage AI biotechnology company focused on Alzheimer’s disease, is gaining investor attention after CEO Ram Mukunda appeared on Bloomberg TV discussing the company’s lead drug candidate, IGC-AD1, a potential fast-acting therapy for agitation associated with Alzheimer’s dementia.

The company recently reported that enrollment in its Phase 2 CALMA clinical trial has reached approximately 80% of its target, marking a significant milestone as IGC advances one of its most closely watched Alzheimer’s therapeutics programs. The company has also expanded its clinical site network and strengthened its intellectual property portfolio, including new patents tied to its proprietary AI-powered drug discovery platform and IGC-AD1. Listen To Full Interview Now!

Alongside IGC Pharma (NYSE: IGC), investors are watching Volato Group, Inc. (NYSE: SOAR), Abits Group Inc. (Nasdaq: ABTS), HUB Cyber Security Ltd. (Nasdaq: HUBC), Hitek Global Inc. (Nasdaq: HKIT), and Kartoon Studios (NYSE: TOON) as these smallcap stocks under $1, high-volume momentum stocks remain active in early trading.

Beyond Alzheimer’s agitation, IGC Pharma is developing additional programs targeting amyloid plaques, neurodegenerative disease, cognitive decline, precision medicine, and neuroscience innovation, positioning the company at the intersection of artificial intelligence and biotechnology.

 

Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content.”TSR” is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. “TSR” authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. “TSR” has not been compensated to produce content related to “Any Companies” appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.

Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email: Send Email
Country: United States
Website: http://www.thestreetreports.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: IGC Pharma’s (NYSE: IGC) CEO Appears on Bloomberg TV Discussing Alzheimer’s Fast-Acting IGC-AD1 Pharmaceutical Therapeutic – More Stocks Inside

Sphere 3D Corp. (NASDAQ: ANY) Surges on Acquisition AI Infrastructure Platform Acquisition – More Stocks Inside

Sphere 3D Corp. (NASDAQ: ANY) surged more than 100% in early trading, with over $100 million in shares traded, after announcing the completion of its merger with Cathedra Bitcoin, creating a scaled digital infrastructure platform with 53 megawatts (MW) of operating power capacity and a 100MW+ expansion pipeline targeting AI infrastructure, data centers, high-performance computing (HPC), and digital asset markets.

The transaction transforms Sphere 3D into a larger AI infrastructure and digital power platform operating five data centers across Iowa, Kentucky, and Tennessee. The combined company also maintains approximately 1.2 EH/s of installed mining capacity while gaining exposure to rapidly growing markets tied to AI data centers, GPU compute, cloud infrastructure, and machine learning.

The timing is significant as the global AI boom increasingly collides with one critical constraint: power availability. Industry experts are shifting their focus beyond chips and GPUs toward the infrastructure needed to support the next generation of compute-intensive workloads. According to the International Energy Agency (IEA), global data center electricity demand is expected to nearly double by 2030 as AI adoption accelerates worldwide.

Alongside Sphere 3D Corp. (NASDAQ: ANY) Watch: Robo.ai Inc. (NASDAQ: AIIO), Genenta Science (Nasdaq: GNTA) Optimum Communications, Inc. (NYSE: OPTU), The GrowHub Ltd (NASDAQ: TGHL) and Peraso Inc. (NASDAQ: PRSO) active now in early trading.

Management believes the combined platform’s existing power footprint, diversified operations, and infrastructure-first strategy position the company to evaluate opportunities across AI model training, high-performance computing, GPU hosting, and other power-intensive applications.

“Closing this combination marks a significant milestone,” said Joel Block, Chief Executive Officer of the Combined Company. “Together, we offer 53 MW of operational capacity, a pipeline exceeding 100 MW of potential expansion, and a NASDAQ-listed platform designed for scalability.”

For investors, the story extends beyond bitcoin mining. With operating infrastructure already in place, a growing expansion pipeline, and increasing exposure to AI infrastructure and digital power markets, Sphere 3D is positioning itself at the intersection of some of the fastest-growing themes in technology.

Bottom Line: As demand for AI infrastructure, data centers, and compute power continues to accelerate, companies controlling scalable energy assets may become increasingly valuable. With 53MW of operating capacity, a 100MW+ development pipeline, and growing exposure to AI-driven markets, Sphere 3D Corp. (NASDAQ: ANY) is emerging as a company investors are watching closely.

 

Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content.”TSR” is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. “TSR” authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. “TSR” has not been compensated to produce content related to “Any Companies” appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.

Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email: Send Email
Country: United States
Website: http://www.thestreetreports.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Sphere 3D Corp. (NASDAQ: ANY) Surges on Acquisition AI Infrastructure Platform Acquisition – More Stocks Inside

Cancer Anorexia Market Shows Strong Future Potential with Increasing Industry Investments by 2036 – DelveInsight | Helsinn Healthcare, Artelo Biosciences, NGM Biopharma

The Key Cancer Anorexia Companies in the market include – Helsinn Healthcare, Artelo Biosciences, NGM Biopharmaceuticals, and others.

 

DelveInsight’s “Cancer Anorexia Market Insights, Epidemiology, and Market Forecast-2036″ report offers an in-depth understanding of the Cancer Anorexia, historical and forecasted epidemiology as well as the Cancer Anorexia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

Get a Free sample for the Cancer Anorexia Market Report

https://www.delveinsight.com/report-store/cancer-anorexia-market

 

Some of the key facts of the Cancer Anorexia Market Report:

  • The cancer anorexia market size was valued at around USD 500 million in 2025 and is anticipated to witness significant growth during the forecast period from 2026 to 2036.

  • In November 2025, Artelo Biosciences provided business highlights. The interim Phase II Cancer Appetite Recovery Study (CAReS) results demonstrated meaningful efficacy, safety, and functional benefit in cancer-related anorexia and weight loss. Patients receiving top-dose ART27.13 achieved an average +6.4% weight gain.

  • In September 2025, Encouraging interim findings from the Phase 2 Cancer Appetite Recovery Study (CAReS), a pivotal trial assessing the investigational cannabinoid receptor agonist ART27.13 for the treatment of Cancer Anorexia-Cachexia Syndrome (CACS), indicate that the therapy could represent a promising new treatment approach for this condition, which affects up to 80% of patients with cancer and currently lacks FDA-approved therapies. The CAReS trial (EudraCT-2022-000464-27) is a Phase 1/2 randomized, placebo-controlled study designed to evaluate the efficacy, safety, and tolerability of ART27.13 in patients with CACS.

  • Among the 7MM, the US accounted for the highest number of incident cases of cancer anorexia with ~285,600 cases in 2025.

  • Among EU4 and the UK, Germany accounted for the highest number of incident cases of cancer anorexia, while Spain accounted for the fewest incident cases.

  • Among all cancer types, lung cancer accounts for the highest incidence of cancer anorexia in the US.

  • In 2025, the incident cases of pancreatic cancer were ~67,440, and incident cases of lung cancer were ~226,650 in the US.

  • According tosecondary analysis, an estimated 72,680 people in the US will be diagnosed with cancer of the oral cavity, pharynx, or larynx, which are the major types of HNC in 2025.

  • As per studies, nearly 153,000 new cases of CRC in 2025, with men expected to represent a slightly higher number of cases than women.

  • Key Cancer Anorexia Companies: Helsinn Healthcare, Artelo Biosciences, NGM Biopharmaceuticals, and others

  • Key Cancer Anorexia Therapies: ADLUMIZ/EDOLMIZU, Adlumiz, ART27.13, NGM120, and others

  • The Cancer Anorexia epidemiology based on gender analyzed that Cancer Anorexia occurs in both men and women

  • The Cancer Anorexia market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Cancer Anorexia pipeline products will significantly revolutionize the Cancer Anorexia market dynamics.

 

Cancer Anorexia Overview

The cancer anorexia-cachexia syndrome (CACS), which includes anorexia, is a common sign of cancer.Reduced intake is caused by a lack of appetite or a loss of desire to eat, however this alone cannot explain the complex changes that characterize the CACS.

 

To Know in detail about the Cancer Anorexia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Cancer Anorexia Market Forecast

 

Cancer Anorexia Epidemiology

The Cancer Anorexia epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Cancer Anorexia Epidemiology Segmentation:

The Cancer Anorexia market report proffers epidemiological analysis for the study period 2022–2036 in the 7MM segmented into:

  • Total Incident Cases of Selected Indications

  • Total Incident Cases Cancer Anorexia

  • Treated Cases of Cancer Anorexia

 

Download the report to understand which factors are driving Cancer Anorexia epidemiology trends @ Cancer Anorexia Epidemiology Forecast

 

Cancer Anorexia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Cancer Anorexia market or expected to get launched during the study period. The analysis covers Cancer Anorexia market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Cancer Anorexia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Cancer Anorexia Therapies and Key Companies

  • ADLUMIZ/EDOLMIZU: Helsinn Healthcare

  • Adlumiz: Helsinn Healthcare

  • ART27.13: Artelo Biosciences

  • NGM120: NGM Biopharmaceuticals

 

Discover more about therapies set to grab major Cancer Anorexia market share @ Cancer Anorexia Treatment Market

 

Cancer Anorexia Market Drivers

  • Rising Global Cancer Burden: The increasing prevalence of various cancers worldwide is significantly driving the incidence of cancer-related anorexia and cachexia conditions.

  • Growing Awareness of Supportive Cancer Care: Increasing focus on improving quality of life and nutritional management in oncology care is supporting the demand for cancer anorexia therapies.

  • Advancements in Therapeutic Development: Ongoing research into appetite stimulants, anti-inflammatory agents, hormonal therapies, and targeted treatments is expanding the therapeutic landscape.

  • Increasing Geriatric Population: The aging population, which is more vulnerable to cancer and associated complications such as anorexia, is contributing to market growth.

 

Cancer Anorexia Market Barriers

  • Limited Approved Treatment Options: The market currently has a limited number of approved therapies specifically targeting cancer anorexia, restricting treatment availability.

  • Complex Disease Mechanism: Cancer anorexia is influenced by multiple metabolic, inflammatory, and psychological factors, making treatment development challenging.

  • Difficulty in Early Diagnosis: Symptoms of cancer anorexia are often underrecognized or overlap with other cancer-related complications, leading to delayed diagnosis and treatment.

  • High Clinical Trial Failure Rates: Challenges in demonstrating consistent efficacy and safety outcomes may hinder the development and approval of new therapies.

 

Scope of the Cancer Anorexia Market Report

  • Study Period: 2022–2036

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Cancer Anorexia Companies: Helsinn Healthcare, Artelo Biosciences, NGM Biopharmaceuticals, and others

  • Key Cancer Anorexia Therapies: ADLUMIZ/EDOLMIZU, Adlumiz, ART27.13, NGM120, and others

  • Cancer Anorexia Therapeutic Assessment: Cancer Anorexia current marketed and Cancer Anorexia emerging therapies

  • Cancer Anorexia Market Dynamics: Cancer Anorexia market drivers and Cancer Anorexia market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Cancer Anorexia Unmet Needs, KOL’s views, Analyst’s views, Cancer Anorexia Market Access and Reimbursement

 

To know more about Cancer Anorexia companies working in the treatment market, visit @ Cancer Anorexia Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Cancer Anorexia Market Report Introduction

2. Executive Summary for Cancer Anorexia

3. SWOT analysis of Cancer Anorexia

4. Cancer Anorexia Patient Share (%) Overview at a Glance

5. Cancer Anorexia Market Overview at a Glance

6. Cancer Anorexia Disease Background and Overview

7. Cancer Anorexia Epidemiology and Patient Population

8. Country-Specific Patient Population of Cancer Anorexia

9. Cancer Anorexia Current Treatment and Medical Practices

10. Cancer Anorexia Unmet Needs

11. Cancer Anorexia Emerging Therapies

12. Cancer Anorexia Market Outlook

13. Country-Wise Cancer Anorexia Market Analysis (2022–2036)

14. Cancer Anorexia Market Access and Reimbursement of Therapies

15. Cancer Anorexia Market Drivers

16. Cancer Anorexia Market Barriers

17. Cancer Anorexia Appendix

18. Cancer Anorexia Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: https://www.delveinsight.com/
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Cancer Anorexia Market Shows Strong Future Potential with Increasing Industry Investments by 2036 – DelveInsight | Helsinn Healthcare, Artelo Biosciences, NGM Biopharma

Food Allergy Market Expected to Experience Accelerated Growth and Market Evolution by 2036 – DelveInsight | Novartis, Roche, ARS Pharma, ALK Abelló, Alfresa Pharma, Stallergenes Greer, DBV Techno

The Key Food Allergy Companies in the market include – Novartis, Roche, ARS Pharmaceuticals, ALK Abelló, Alfresa Pharma, Stallergenes Greer, DBV Technologies, Aravax, Aimmune Therapeutics, Inc., Novartis Pharmaceuticals, DBV Technologies, Intrommune Therapeutics, Xencor, Vedanta Biosciences, Alladapt Immunotherapeutics, Aravax, Regeneron, DBV Technologies, Novartis AG, Camallergy, Genentech, GI Innovation, and others.

 

DelveInsight’s “Food Allergy Market Insights, Epidemiology, and Market Forecast-2036″ report offers an in-depth understanding of the Food Allergy, historical and forecasted epidemiology as well as the Food Allergy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

Get a Free sample for the Food Allergy Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/food-allergy-market-insights

 

Some of the key facts of the Food Allergy Market Report:

  • The food allergy market size was valued at around USD 3,500 million in 2025 and is expected to reach approximately USD 10,500 million by 2036, expanding at a CAGR of 9% during the forecast period from 2026 to 2036.

  • In February 2026, Aquestive Therapeutics announced that it received a Complete Response Letter (CRL) from the FDA on January 30, 2026, for the New Drug Application (NDA) seeking approval of ANAPHYLM (dibutepinephrine) Sublingual Film for the treatment of Type I allergic reactions, including anaphylaxis, in patients weighing 30kg or more (approximately 66 pounds).

  • In February 2026, according to Novartis’ Q4 2025 presentation, initiation of the Phase III program for remibrutinib is anticipated in the second half of 2026.

  • In August 2025, Stallergenes Greer announced to voluntarily discontinue PALFORZIA by July 31, 2026, not due to safety, quality, or efficacy concerns. The company will fulfill regulatory obligations and support a smooth transition for patients and healthcare providers.

  • In March 2025, DBV Technologies reached an understanding with the US Food and Drug Administration (FDA) based on written responses to its Type D Investigational New Drug (IND) meeting request. The FDA concurred with DBV’s proposal that safety exposure data from the VITESSE Phase III study of the Viaskin Peanut Patch in children aged 4-7 years would be sufficient to support BLA filing for this age group, thereby accelerating the anticipated timeline for BLA submission to the first half of 2026.

  • In March 2025, the US FDA approved NEFFY for the treatment of Type I allergic reactions, including anaphylaxis, in children who are aged 4 years and older and weigh 15 to 35 years.

  • In February 2025, researchers at Imperial College’s National Heart & Lung Institute (NHLI) shared promising results from the initial phase of clinical trials for a novel peanut allergy vaccine. Working alongside industry partner Allergy Therapeutics, the Imperial team developed the vaccine using virus-like particle (VLP) technology to deliver the peanut allergen protein Ara h2. According to their recent publication in the Journal of Allergy and Clinical Immunology (JACI), the Phase 1 first-in-human trial confirmed the vaccine’s safety and tolerability, showing no allergic reactions during skin prick tests when compared to control treatments.

  • At present, omalizumab (XOLAIR), epinephrine nasal spray (NEFFY), and peanut allergen powder (PALFORZIA) are among the approved therapies providing key treatment options for food allergy patients. However, Stallergenes Greer has announced that it will discontinue the commercialization of PALFORZIA effective July 31, 2026, a decision unrelated to the product’s safety, efficacy, or quality.

  • According to DelveInsight’s estimates, the total diagnosed prevalent cases of Food Allergy in the 7MM were approximately 61,000,000 in 2025.

  • Among the EU4 and the UK, Spain accounted for the highest number of diagnosed prevalent cases of Food Allergy, followed by Germany, whereas France accounted for the lowest number of cases in 2025.

  • In 2025, among gender-specific cases of food allergy in 7 million individuals, males accounted for 53% while females made up 47%.

  • In Japan in 2025, egg allergy had the highest diagnosed prevalence among food allergens, followed by milk allergy, while fish allergy had the lowest prevalence.

  • Key Food Allergy Companies: Aimmune Therapeutics, Inc., Novartis Pharmaceuticals, DBV Technologies, Intrommune Therapeutics, Xencor, Vedanta Biosciences, Alladapt Immunotherapeutics, Aravax, Regeneron, DBV Technologies, Novartis AG, Camallergy, Genentech, GI Innovation, and others

  • Key Food Allergy Therapies: Omalizumab (XOLAIR), Epinephrine /Adrenaline (NEFFY/ EURNEFFY), Peanut allergen powder-dnfp (PALFORZIA), Viaskin (DBV712) Peanut Patch, PVX108 (AVX-201), Palforzia, Ligelizumab, Viaskin Peanut, INT301, AIMab7195, VE416, ADP101, PVX-108, Dupilumab, DBV 135, Ligelizumab, CA002, Omalizumab, GI 301, and others

  • The Food Allergy market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Food Allergy pipeline products will significantly revolutionize the Food Allergy market dynamics.

 

Food Allergy Overview

A food allergy develops when the immune system identifies a particular food as harmful and responds by triggering symptoms, which is known as an allergic reaction. These allergic reactions are caused by allergens, which are specific foods that induce immune responses in susceptible individuals.

 

To Know in detail about the Food Allergy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Food Allergy Market Forecast

 

Food Allergy Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Food Allergy Epidemiology Segmentation:

The Food Allergy market report proffers epidemiological analysis for the study period 2022–2036 in the 7MM segmented into:

  • Total Diagnosed Prevalent Cases of Food Allergy

  • Allergen-specific Diagnosed Prevalent Cases of Food Allergy

  • Gender-Specific Diagnosed Prevalent Cases of Food Allergy

  • Severity-specific Diagnosed Prevalent Cases of Food Allergy

  • Total treated cases of Food Allergy

 

Download the report to understand which factors are driving Food Allergy epidemiology trends @ Food Allergy Epidemiology Forecast

 

Food Allergy Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Food Allergy market or expected to get launched during the study period. The analysis covers Food Allergy market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Food Allergy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Food Allergy Therapies and Key Companies

  • Omalizumab (XOLAIR): Novartis/ Roche

  • Epinephrine /Adrenaline (NEFFY/ EURNEFFY): ARS Pharmaceuticals /ALK Abelló /Alfresa Pharma

  • Peanut allergen powder-dnfp (PALFORZIA): Stallergenes Greer

  • Viaskin (DBV712) Peanut Patch: DBV Technologies

  • PVX108 (AVX-201): Aravax

  • INT301: Intrommune Therapeutics

  • AIMab7195: Xencor

  • VE416: Vedanta Biosciences

  • ADP101: Alladapt Immunotherapeutics

  • PVX-108: Aravax

  • Dupilumab: Regeneron

  • DBV 135: DBV Technologies

  • Ligelizumab: Novartis AG

  • CA002: Camallergy

  • Omalizumab: Genentech

  • GI 301: GI Innovation

 

Discover more about therapies set to grab major Food Allergy market share @ Food Allergy Treatment Landscape

 

Food Allergy Market Drivers

  • Rising Prevalence of Food Allergies: The increasing incidence of food allergies among children and adults worldwide is a major factor driving market growth.

  • Growing Awareness and Diagnosis Rates: Improved awareness regarding allergic reactions and advancements in diagnostic testing are leading to earlier and more accurate diagnosis of food allergies.

  • Advancements in Immunotherapy Treatments: The development of oral immunotherapy, biologics, and desensitization therapies is expanding treatment options for food allergy patients.

  • Increasing Demand for Emergency Allergy Medications: Growing use of epinephrine auto-injectors and antihistamine therapies is supporting market expansion.

  • Strong Pipeline Development: Ongoing clinical trials and increased investments in allergy-focused research are accelerating the introduction of innovative therapies.

 

Food Allergy Market Barriers

  • High Cost of Advanced Therapies: Innovative biologics and immunotherapy treatments can be expensive, limiting affordability for many patients.

  • Limited Curative Treatment Options: Most currently available therapies focus on symptom management rather than providing a permanent cure for food allergies.

  • Risk of Severe Allergic Reactions: Concerns regarding anaphylaxis and adverse reactions during immunotherapy may impact treatment adoption.

  • Stringent Regulatory Requirements: Complex clinical trial and regulatory approval processes may delay the commercialization of new food allergy therapies.

  • Underdiagnosis in Developing Regions: Limited awareness, inadequate healthcare infrastructure, and lack of specialized allergy testing facilities may hinder diagnosis and treatment in emerging markets.

 

Scope of the Food Allergy Market Report

  • Study Period: 2022–2036

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Food Allergy Companies: Novartis, Roche, ARS Pharmaceuticals, ALK Abelló, Alfresa Pharma, Stallergenes Greer, DBV Technologies, Aravax, Aimmune Therapeutics, Inc., Novartis Pharmaceuticals, DBV Technologies, Intrommune Therapeutics, Xencor, Vedanta Biosciences, Alladapt Immunotherapeutics, Aravax, Regeneron, DBV Technologies, Novartis AG, Camallergy, Genentech, GI Innovation, and others

  • Key Food Allergy Therapies: Omalizumab (XOLAIR), Epinephrine /Adrenaline (NEFFY/ EURNEFFY), Peanut allergen powder-dnfp (PALFORZIA), Viaskin (DBV712) Peanut Patch, PVX108 (AVX-201), Palforzia, Ligelizumab, Viaskin Peanut, INT301, AIMab7195, VE416, ADP101, PVX-108, Dupilumab, DBV 135, Ligelizumab, CA002, Omalizumab, GI 301, and others

  • Food Allergy Therapeutic Assessment: Food Allergy current marketed and Food Allergy emerging therapies

  • Food Allergy Market Dynamics: Food Allergy market drivers and Food Allergy market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Food Allergy Unmet Needs, KOL’s views, Analyst’s views, Food Allergy Market Access and Reimbursement

 

To know more about Food Allergy companies working in the treatment market, visit @ Food Allergy Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Food Allergy Market Report Introduction

2. Executive Summary for Food Allergy

3. SWOT analysis of Food Allergy

4. Food Allergy Patient Share (%) Overview at a Glance

5. Food Allergy Market Overview at a Glance

6. Food Allergy Disease Background and Overview

7. Food Allergy Epidemiology and Patient Population

8. Country-Specific Patient Population of Food Allergy

9. Food Allergy Current Treatment and Medical Practices

10. Food Allergy Unmet Needs

11. Food Allergy Emerging Therapies

12. Food Allergy Market Outlook

13. Country-Wise Food Allergy Market Analysis (2022–2036)

14. Food Allergy Market Access and Reimbursement of Therapies

15. Food Allergy Market Drivers

16. Food Allergy Market Barriers

17. Food Allergy Appendix

18. Food Allergy Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: https://www.delveinsight.com/
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Food Allergy Market Expected to Experience Accelerated Growth and Market Evolution by 2036 – DelveInsight | Novartis, Roche, ARS Pharma, ALK Abelló, Alfresa Pharma, Stallergenes Greer, DBV Techno

Epilepsy Market Unlocking New Revenue Opportunities and Strategic Expansion by 2036 – DelveInsight | ES Therapeutics, PhytoTech Therapeutics, UCB Biopharma, SK Life Science

The Key Epilepsy Companies in the market include – Aquestive Therapeutics, Atnahs Pharma (Pharmanovia), Jazz Pharmaceuticals, SK Biopharmaceutical, Angelini Pharma/Ono Pharmaceutical, Novartis, Xenon Pharmaceuticals, Takeda, Ovid Therapeutics, Biohaven Pharmaceuticals/Knopp Biosciences, and others.

 

DelveInsight’s “Epilepsy Market Insights, Epidemiology, and Market Forecast-2036″ report offers an in-depth understanding of the Epilepsy, historical and forecasted epidemiology as well as the Epilepsy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

Get a Free sample for the Epilepsy Market Report

https://www.delveinsight.com/report-store/epilepsy-market

 

Some of the key facts of the Epilepsy Market Report:

  • The epilepsy market size across the 7MM was valued at approximately USD 9 billion in 2023 and is projected to expand at a CAGR of 7% during the forecast period from 2026 to 2036, supported by rising disease prevalence and ongoing advancements in therapeutic options.

  • In March 2026, Xenon Pharmaceuticals announced positive topline results from the Phase III (X-TOLE2) study of azetukalner in focal onset seizures (FOS). Xenon anticipates submitting a New Drug Application for azetukalner in FOS to the U.S. FDA in Q3 2026. If approved, azetukalner would be the only KV7 potassium channel opener available for the treatment of epilepsy.

  • In January 2026, Biohaven Pharmaceuticals announced preliminary data from an ongoing open-label extension (OLE) study of opakalim, a selective Kv7 channel activator, in focal epilepsy, with pivotal results in the indication expected in 2026.

  • In April 2025, Neurelis announced FDA approval of VALTOCO (diazepam nasal spray) for the short-term treatment of seizure clusters (acute repetitive seizures) in patients aged 2 years and older.

  • In September 2025, Actio Biosciences gave the first dose to a participant in the Phase Ia clinical trial of ABS-1230, a KCNT1 (potassium sodium-activated channel subfamily T member 1) inhibitor designed for epilepsy treatment. The trial is a double-blind, randomized, placebo-controlled study assessing single and multiple ascending doses and the impact of food in healthy volunteers. Conducted in Australia, the study will evaluate the pharmacokinetics, safety, and tolerability of ABS-1230.

  • In June 2025, Epiminder, a leader in implantable continuous EEG monitoring (iCEM™), has announced the publication of findings from its pivotal UMPIRE (sUb-scalp Monitoring ePileptic seIzuREs) trial in Epilepsia. The study, carried out at major hospitals in Australia, confirmed the safety and effectiveness of iCEM™, showing that the system can record high-quality EEG data over long durations, comparable to conventional scalp-based EEG monitoring.

  • In May 2025, Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotech company focused on developing small molecule precision therapies for neurological and psychiatric conditions, announced its financial results for the first quarter ending March 31, 2025, along with a business update. The company described 2025 as a pivotal year, as it moves toward presenting initial proof-of-concept data for RAP-219 from its Phase 2a trial in patients with refractory focal epilepsy and advances its pipeline-in-a-product approach by launching a clinical trial for bipolar mania.

  • In April 2025, In a Phase Ib/IIa trial, Lundbeck’s receptor superagonist, developed to treat seizures linked to developmental and epileptic encephalopathies (DEEs), demonstrated a 61.2% reduction in total seizures. Interim data from the open-label extension (OLE) of the Pacific trial (NCT05364021), which evaluated bexicaserin, an oral 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, in patients previously on placebo, revealed a 57.3% decrease in countable motor seizures and a 61.2% reduction in total seizures in those who had switched from placebo.

  • In March 2025, QurAlis Corporation, a clinical-stage biotechnology company focused on developing precision medicines for neurodegenerative and neurological diseases, announced positive topline results from its Phase 1 proof-of-mechanism (PoM) clinical trial of QRL-101. The study, conducted in healthy volunteers, assessed biomarkers associated with amyotrophic lateral sclerosis (ALS) and epilepsy.

  • Several anti-epileptic drugs (AEDs) have received approval and are widely available as generics, including lamotrigine, sodium valproate, carbamazepine, levetiracetam, and topiramate. Newer approved therapies include Azetukalner (XCOPRI), Ganaxolone (ZTALMY), Perampanel (FYCOMPA), Diazepam (LIBERVANT), intranasal Midazolam (NAYZILAM), Cannabidiol (EPIDIOLEX), Brivaracetam (BRIVIACT), and Clobazam oral soluble film (SYMPAZAN).

  • The epilepsy treatment landscape is evolving from symptomatic seizure control to mechanism-driven and precision therapies, particularly in drug-resistant and rare epileptic syndromes.

  • Drug-resistant epilepsy (~30–40% of patients) remains a major unmet need, driving the development of novel agents targeting ion channels, synaptic transmission, and neuroinflammation.

  • According to global epidemiological estimates, in 2025, the total number of individuals living with Epilepsy is ~50–70 million worldwide, making it one of the most common chronic neurological disorders globally.

  • The US had the highest cases of epilepsy, of which nearly 67% of the cases were focal epileptic seizures, 31% were generalized epileptic seizures, while 2% of the cases were other determined or undetermined epileptic seizures.

  • Epidemiological studies indicate that the prevalence of epilepsy in the general population is approximately ~0.5–1.0% (5–10 per 1,000 individuals), with a higher burden observed in low- and middle-income countries due to increased risk factors and limited access to care.

  • Focal epilepsy accounts for ~67% of all cases, while generalized epilepsy represents ~20–30%, with the remaining cases classified as unknown or combined onset types.

  • Secondary epidemiological analyses highlight that incidence follows a bimodal age distribution, with peaks in early childhood and adults over 60 years, largely driven by genetic causes in pediatric patients and cerebrovascular disease in older adults.

  • The prevalence of epilepsy is reported to be slightly higher in males than females in several population-based studies, although gender differences are generally modest and vary by region and underlying etiology.

  • Key Epilepsy Companies: Aquestive Therapeutics, Atnahs Pharma (Pharmanovia), Jazz Pharmaceuticals, SK Biopharmaceutical, Angelini Pharma/Ono Pharmaceutical, Novartis, Xenon Pharmaceuticals, Takeda, Ovid Therapeutics, Biohaven Pharmaceuticals/Knopp Biosciences, and others

  • Key Epilepsy Therapies: LIBERVANT (diazepam buccal film), EPIDIOLEX/EPIDYOLEX (cannabidiol), XCOPRI/ONTOZRY (cenobamate), AFINITOR DISPERZ/VOTUBIA (everolimus), XEN1101/Azetukalner, Soticlestat (TAK-935), BHV-7000 (KB-3061), and others

  • The Epilepsy market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Epilepsy pipeline products will significantly revolutionize the Epilepsy market dynamics.

 

To Know in detail about the Epilepsy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Epilepsy Market Forecast

 

Epilepsy Overview

Epilepsy is a neurological disorder characterized by recurrent, unprovoked seizures caused by abnormal electrical activity in the brain. Seizures can vary in severity and may involve changes in behavior, consciousness, muscle control, or sensory perception. The condition can develop at any age and may result from various factors, including genetics, brain injury, infections, or structural brain abnormalities. Epilepsy is typically managed with medication, lifestyle adjustments, and sometimes surgery for more severe cases.

 

Epilepsy Epidemiology

The Epilepsy epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Epilepsy Epidemiology Segmentation:

The Epilepsy market report proffers epidemiological analysis for the study period 2022–2036 in the 7MM segmented into:

  • Total Prevalent Population of Epilepsy

  • Total Diagnosed Prevalent Population of Epilepsy

  • Gender-specific Diagnosed Prevalence of Epilepsy

  • Diagnosed Prevalence of Epilepsy Based on Seizure Types in Adults

  • Diagnosed Prevalence of Epilepsy Based on Seizure Types in Children

 

Download the report to understand which factors are driving Epilepsy epidemiology trends @ Epilepsy Epidemiology Forecast

 

Epilepsy Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Epilepsy market or expected to get launched during the study period. The analysis covers Epilepsy market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Epilepsy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Epilepsy Therapies and Key Companies

  • Diazepam (VALTOCO): Neurelis/Aculys Pharma

  • Cannabidiol (EPIDIOLEX): Greenwich Biosciences/Jazz Pharmaceuticals

  • Cenobamate (XCOPRI): SK Biopharmaceuticals

  • LIBERVANT (diazepam buccal film): Aquestive Therapeutics/Atnahs Pharma (Pharmanovia)

  • EPIDIOLEX/EPIDYOLEX (cannabidiol): Jazz Pharmaceuticals

  • XCOPRI/ONTOZRY (cenobamate): SK Biopharmaceutical/Angelini Pharma/Ono Pharmaceutical

  • AFINITOR DISPERZ/VOTUBIA (everolimus): Novartis

  • XEN1101/Azetukalner: Xenon Pharmaceuticals

  • Soticlestat (TAK-935): Takeda/Ovid Therapeutics

  • BHV-7000 (KB-3061): Biohaven Pharmaceuticals/Knopp Biosciences

 

Discover more about therapies set to grab major Epilepsy market share @ Epilepsy Treatment Market

 

Epilepsy Market Drivers

  • Rising Prevalence of Epilepsy: The increasing global burden of epilepsy and seizure-related disorders is significantly driving demand for effective treatment options.

  • Advancements in Anti-Epileptic Therapies: Continuous development of novel anti-epileptic drugs (AEDs), targeted therapies, and improved drug formulations is supporting market growth.

  • Growing Awareness and Early Diagnosis: Increasing awareness campaigns, improved neurological screening, and better access to healthcare services are leading to earlier diagnosis and treatment initiation.

  • Strong Pipeline and Research Activities: Ongoing clinical trials and increased investments in neuroscience research are accelerating the development of innovative epilepsy therapies.

 

Epilepsy Market Barriers

  • Availability of Generic Drugs: The widespread availability of low-cost generic anti-epileptic drugs creates pricing pressure for branded therapies.

  • Drug Resistance in Patients: A significant proportion of epilepsy patients experience drug-resistant seizures, limiting the effectiveness of existing therapies.

  • Side Effects Associated with AEDs: Long-term use of anti-epileptic medications may lead to adverse effects such as dizziness, fatigue, cognitive impairment, and mood disorders, impacting patient adherence.

  • High Cost of Advanced Therapies: Innovative biologics, surgical procedures, and neurostimulation devices can be expensive, restricting accessibility in low- and middle-income regions.

  • Limited Access to Specialized Care: Inadequate availability of neurologists, epilepsy centers, and diagnostic infrastructure in certain regions may hinder timely treatment.

 

Scope of the Epilepsy Market Report

  • Study Period: 2022–2036

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Epilepsy Companies: Aquestive Therapeutics, Atnahs Pharma (Pharmanovia), Jazz Pharmaceuticals, SK Biopharmaceutical, Angelini Pharma/Ono Pharmaceutical, Novartis, Xenon Pharmaceuticals, Takeda, Ovid Therapeutics, Biohaven Pharmaceuticals/Knopp Biosciences, and others

  • Key Epilepsy Therapies: LIBERVANT (diazepam buccal film), EPIDIOLEX/EPIDYOLEX (cannabidiol), XCOPRI/ONTOZRY (cenobamate), AFINITOR DISPERZ/VOTUBIA (everolimus), XEN1101/Azetukalner, Soticlestat (TAK-935), BHV-7000 (KB-3061), and others

  • Epilepsy Therapeutic Assessment: Epilepsy current marketed and Epilepsy emerging therapies

  • Epilepsy Market Dynamics: Epilepsy market drivers and Epilepsy market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Epilepsy Unmet Needs, KOL’s views, Analyst’s views, Epilepsy Market Access and Reimbursement

 

To know more about Epilepsy companies working in the treatment market, visit @ Epilepsy Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Epilepsy Market Report Introduction

2. Executive Summary for Epilepsy

3. SWOT analysis of Epilepsy

4. Epilepsy Patient Share (%) Overview at a Glance

5. Epilepsy Market Overview at a Glance

6. Epilepsy Disease Background and Overview

7. Epilepsy Epidemiology and Patient Population

8. Country-Specific Patient Population of Epilepsy

9. Epilepsy Current Treatment and Medical Practices

10. Epilepsy Unmet Needs

11. Epilepsy Emerging Therapies

12. Epilepsy Market Outlook

13. Country-Wise Epilepsy Market Analysis (2022–2036)

14. Epilepsy Market Access and Reimbursement of Therapies

15. Epilepsy Market Drivers

16. Epilepsy Market Barriers

17. Epilepsy Appendix

18. Epilepsy Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: https://www.delveinsight.com/
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Epilepsy Market Unlocking New Revenue Opportunities and Strategic Expansion by 2036 – DelveInsight | ES Therapeutics, PhytoTech Therapeutics, UCB Biopharma, SK Life Science